BRISTOL-MYERS SQUIBB COMPANY Debt Securities, Available-for-sale
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Debt Securities, Available-for-sale of $496.00 million as of 2023-09-30, per its 10-Q filed 2023-10-26.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2023-10-26
- 2023-09-30: Debt Securities, Available-for-sale $496.00M.
- 2023-06-30: Debt Securities, Available-for-sale $358.00M.
- 2023-03-31: Debt Securities, Available-for-sale $274.00M.
- 2022-12-31: Debt Securities, Available-for-sale $130.00M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2023-09-30 | $496.00M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $358.00M 10-Q · filed 2023-07-27 |
| 2023-03-31 | $274.00M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $130.00M 10-Q · filed 2023-10-26 |
| 2022-09-30 | $1.29B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $2.48B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $2.60B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $2.99B 10-K · filed 2023-02-14 |
| 2021-09-30 | $2.17B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $2.09B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $2.24B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $1.72B 10-K · filed 2022-02-09 |
| 2020-09-30 | $2.21B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.25B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.16B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $3.81B 10-K · filed 2021-02-10 |
| 2019-09-30 | $2.98B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $1.95B 10-Q · filed 2019-07-25 |
| 2019-03-31 | $2.66B 10-Q · filed 2019-04-25 |
| 2018-12-31 | $3.62B 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |